Susquehanna International Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,500
Closed -$204K 13392
2026
Q1
$204K Buy
+2,500
New +$207K ﹤0.01% 11666
2025
Q1
Sell
-4,400
Closed -$223K 12491
2024
Q4
$223K Sell
4,400
-200
-4% -$11.9K ﹤0.01% 10477
2024
Q3
$293K Sell
4,600
-4,400
-49% -$284K ﹤0.01% 9650
2024
Q2
$533K Sell
9,000
-12,200
-58% -$675K ﹤0.01% 8119
2024
Q1
$1.22M Buy
21,200
+3,700
+21% +$215K ﹤0.01% 6419
2023
Q4
$998K Sell
17,500
-6,700
-28% -$314K ﹤0.01% 6999
2023
Q3
$1.16M Buy
24,200
+900
+4% +$46.2K ﹤0.01% 6299
2023
Q2
$1.21M Sell
23,300
-11,600
-33% -$639K ﹤0.01% 6244
2023
Q1
$1.89M Buy
34,900
+16,000
+85% +$903K ﹤0.01% 5260
2022
Q4
$1.09M Sell
18,900
-14,600
-44% -$822K ﹤0.01% 5993
2022
Q3
$1.6M Buy
33,500
+4,600
+16% +$245K ﹤0.01% 5449
2022
Q2
$1.4M Sell
28,900
-2,700
-9% -$137K ﹤0.01% 5717
2022
Q1
$1.96M Buy
31,600
+800
+3% +$49.1K ﹤0.01% 5526
2021
Q4
$2.5M Sell
30,800
-42,100
-58% -$3.61M ﹤0.01% 5002
2021
Q3
$6.92M Buy
72,900
+20,900
+40% +$2.11M ﹤0.01% 3425
2021
Q2
$5.12M Buy
52,000
+20,500
+65% +$1.79M ﹤0.01% 3991
2021
Q1
$2.63M Sell
31,500
-16,400
-34% -$1.55M ﹤0.01% 5257
2020
Q4
$4.13M Sell
47,900
-24,200
-34% -$1.87M ﹤0.01% 3745
2020
Q3
$5.06M Sell
72,100
-52,200
-42% -$3.7M ﹤0.01% 3024
2020
Q2
$9.02M Buy
124,300
+93,000
+297% +$5.94M ﹤0.01% 2255
2020
Q1
$1.45M Sell
31,300
-8,700
-22% -$485K ﹤0.01% 4564
2019
Q4
$2.47M Sell
40,000
-19,000
-32% -$1.01M ﹤0.01% 3981
2019
Q3
$2.51M Sell
59,000
-2,600
-4% -$123K ﹤0.01% 3782
2019
Q2
$3.19M Sell
61,600
-17,300
-22% -$861K ﹤0.01% 3349
2019
Q1
$4.38M Buy
78,900
+18,900
+32% +$1.02M ﹤0.01% 2615
2018
Q4
$2.52M Buy
60,000
+16,300
+37% +$850K ﹤0.01% 3174
2018
Q3
$3.04M Sell
43,700
-123,900
-74% -$8.1M ﹤0.01% 3346
2018
Q2
$9.59M Buy
167,600
+26,200
+19% +$1.43M ﹤0.01% 1973
2018
Q1
$7.79M Buy
141,400
+3,500
+3% +$210K ﹤0.01% 2044
2017
Q4
$7.73M Sell
137,900
-118,400
-46% -$6.68M ﹤0.01% 2069
2017
Q3
$15.7M Buy
256,300
+6,400
+3% +$364K 0.01% 1416
2017
Q2
$13.3M Buy
249,900
+142,900
+134% +$6.97M 0.01% 1454
2017
Q1
$5.16M Sell
107,000
-56,000
-34% -$2.6M ﹤0.01% 2327
2016
Q4
$6.5M Sell
163,000
-52,600
-24% -$2.25M ﹤0.01% 2042
2016
Q3
$10.4M Buy
215,600
+152,800
+243% +$7.26M 0.01% 1505
2016
Q2
$2.44M Sell
62,800
-27,300
-30% -$1.18M ﹤0.01% 3245
2016
Q1
$3.68M Sell
90,100
-114,800
-56% -$5.07M ﹤0.01% 2735
2015
Q4
$14.6M Sell
204,900
-89,100
-30% -$5.95M 0.01% 1408
2015
Q3
$17.1M Sell
294,000
-113,000
-28% -$9.63M 0.01% 1346
2015
Q2
$36.8M Buy
407,000
+41,200
+11% +$3.54M 0.02% 867
2015
Q1
$29M Buy
365,800
+176,800
+94% +$13.1M 0.01% 965
2014
Q4
$11.9M Sell
189,000
-68,000
-26% -$3.99M ﹤0.01% 1847
2014
Q3
$13.4M Buy
257,000
+18,200
+8% +$882K 0.01% 1793
2014
Q2
$11.1M Buy
238,800
+13,400
+6% +$529K ﹤0.01% 1999
2014
Q1
$9M Buy
+225,400
New +$10.2M ﹤0.01% 2134

Other funds holding BIB

Susquehanna International Group's BIB Position: Q2 2026 in Review

Susquehanna International Group reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 41% in Q2 2026, selling an estimated $455K and leaving 7,802 shares worth $786K. The position accounts for ﹤0.01% of the portfolio, ranked #8829.

Susquehanna International Group first reported a position in BIB in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.88M in Q3 2020. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Susquehanna International Group held 7,802 shares of ProShares Ultra NASDAQ Biotechnology worth $786K as of Q2 2026.
  • Susquehanna International Group sold 5,410 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $455K.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #8829 holding.
  • Susquehanna International Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's ProShares Ultra NASDAQ Biotechnology position peaked at $3.88M in Q3 2020.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.